Log in
Log in

Join the ATF and take back control of your thyroid health

Join now

Thyroid News Out Now - Issue #54

16 Jul 2017 3:39 PM | Michael Sugg

Here is a selection of the articles available in issue number 54 of "Thyroid News".

Does every thyroid cancer need treatment?
Professor Leigh Delbridge

There are mixed messages in the media about thyroid cancer. On one hand we hear that thyroid cancer, which up until now, had been considered a rare disorder, has shown a dramatic increase in cases worldwide with a tripling of incidence in the USA. In Australia currently, of all malignancies documented in the national cancer registries, thyroid cancer is the most rapidly increasing in females.

Please note you need to be a member to read these articles in full.


Name change of active ingredient of Oroxine, Eutroxsig and Eltroxin to align with international terminology.

Aspen Pharma has written to the ATF (letter included in the edition). The name of the active ingredient of Oroxine, Eutroxsig and Eltroxin has been changed in Australia to align with international terminology. Thyroxine will no longer be the name of the active ingredient, it will be now known in Australia as Levo-thyroxine, which is the international reference. Please be aware when speaking to your GP, Endocrinologist or Pharmacist.

Please note you need to be a member to read these articles in full.




Phone: +61 (0) 447 834 724
(If you would like to organise a phone chat, please email to organise a time, thank you!)

Mailing Address: PO Box 7161, Norwest NSW 2153, Australia


The mission of The Australian Thyroid Foundation Ltd (ATF) is to offer support, information and education to members and their families through the many services provided by The ATF and raise awareness about health consequences of iodine deficiency and the benefits of good thyroid health.

© 2024 Australian Thyroid Foundation - All donations of $2.00 or more to are tax deductiblePrivacy Policy | Terms & Conditions

Powered by Wild Apricot Membership Software